Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

NOVATO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical significance observed between the 6R-BH4 treatment and placebo groups.

The primary endpoint of the study, peak walking time (PWT), did not show a significant difference between 6R-BH4 and placebo, and the secondary endpoint, claudication onset time, also did not show a difference. Addition of Vitamin C to 6R-BH4 did not improve efficacy on PWT. Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did not show a significant benefit with 6R-BH4. Urinary protein excretion did not decrease with 6R-BH4 treatment, though there may have been some effect in the subset of patients with microalbuminuria at baseline. 6R-BH4 was well-tolerated in peripheral arterial disease patients and had a safety profile similar to previous studies.

Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated, "We are disappointed that the results of 6R-BH4 in peripheral arterial disease were not statistically significant. We have upcoming data in several BioMarin and investigator-sponsored studies of 6R-BH4 including proteinuria, pulmonary arterial hypertension and 6R-BH4 plus Vitamin C in patients with endothelial dysfunction. Along with the prior results in sickle cell disease, these data will determine the future of the 6R-BH4 cardiovascular program once all the studies are complete."

Study Design

The Phase 2 multi-center, randomized, double-blind, placebo-controlled study enrolled 190 subjects and was conducted at 31 sites in the U.S. and Argentina. 161 patients comple
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Proove Biosciences , the commercial and research leader in ... between specific genes and patients’ predisposition to anxiety disorders ... 27th Annual Scientific Program in Orlando, Florida. , ... Change.’ Mental health, and healthcare as a whole, is ... by the Affordable Care Act to the growing need ...
(Date:9/23/2014)... 23, 2014 Proove Biosciences , ... industry leading research and data on the association between ... American Academy of Pain Management’ s 25th ... Arizona at the , Proove Biosciences ... and genetic predisposition to opioid misuse risk in chronic ...
(Date:9/23/2014)... CLARA, Calif. , Sept. 23, 2014 ... institution in India devoted to genome-based ... of Biomedical Genomics (NIBMG) is taking a bite out ... common cancer among males in India ... object storage solutions from DataDirect Networks (DDN). , To ...
(Date:9/23/2014)... Sept. 23, 2014   GenoSpace , a precision ... of tools to enable the broad use of genomic ... it has been awarded Phase I of a Fast ... National Institutes of Health (NIH) to enable enhanced data ... - http://photos.prnewswire.com/prnh/20140922/147649 During the ...
Breaking Biology Technology:Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 2Proove Biosciences Will Be Exhibiting New Genetic Research at the 27th Annual US Psych Congress Scientific Program 3Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... , STOCKHOLM, ... European Investment Fund (EIF) has entered into a,co-investment agreement ... Karolinska Development and used to invest in the company,s,portfolio ... to invest 26.7 M Euros in the co-investment fund. ...
... Most people would like to be able to charge ... not too often. A recent discovery made by UC ... that could do just this. In recent ... Bandaru, a professor in the UCSD Department of Mechanical ...
... , BETHESDA, Md., Nov. 19 ... for diabetes therapy, and a provider of technical and regulatory ... today it closed the previously reported $6.3 million registered direct ... stock and warrants to purchase up to 1,104,348 additional shares ...
Cached Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3Nanotube defects equal better energy and storage systems 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
(Date:9/23/2014)... Antarctic fish that manufacture their own "antifreeze" proteins ... suffer an unfortunate side effect, researchers funded by ... ice crystals that accumulate inside their bodies resist ... discovered what appears to be an undesirable consequence ... notothenioid fish," said University of Oregon doctoral student ...
(Date:9/23/2014)... new tissues during the healing process, cells must ... years, scientists believed this communication happened primarily through ... and the University of Pittsburgh have found that ... if not more crucial. The findings, published in ... the National Academy of Sciences , could lead ...
(Date:9/23/2014)... CHAMPAIGN, Ill. Scientists have scoured cow rumens and ... plant cell walls for the production of next-generation biofuels, ... reside in the human lower intestine, researchers report. , ... of the National Academy of Sciences , is the ... that microbes in the human gut can digest fiber, ...
Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3The mechanics of tissue growth 2Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3
... URBANA The first sequencing of the Asiatic pear ... of seven worldwide universities and institutions including the University ... to work on the strategy for sequencing, analyzing the ... the manuscript," said U of I plant molecular geneticist ...
... 12 June, 2012 GE Healthcare, the healthcare business ... genomics organization, jointly announced today a pioneering multi-year research ... collaboration is to help advance the potential global utility ... and toxicity testing by exploring the underlying genetic variation ...
... algae, barnacles, mussels and other organisms is a major ... a joint project, researchers at the University of Gothenburg ... environmentally-friendly and effective bottom paints to prevent this. ... consumption and so increased air pollution. It can also ...
Cached Biology News:Asiatic pear genome sequenced 2BGI, GE Healthcare team up on pioneering stem cell science projects 2New paints prevent fouling of ships' hulls 2
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
... Sensitivity Freezing Point Osmometer for 10 ... volume applications, including pediatric, neonatal, geriatric, ... Automatic Calibration with 2 or ... printer, keypad and software for statistical ...
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
RayBio Human Atherosclerosis Antibody Array 1.1 (4) with Accessory, detects 40 inflammatory factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: